Subject: Withdrawal of H0005845 (company name: CVnCoV, INN: Zorecimeran, COVID-19 mRNA vaccine candidate)

Dear CHMP Chair,

I would like to inform you that, at this point of time, CureVac AG has taken the decision to withdraw the application for Marketing Authorisation of H0005845 (company name: CVnCoV, INN: Zorecimeran, COVID-19 mRNA vaccine candidate), which was intended to be used for active immunisation to prevent COVID-19 caused by SARS-CoV-2.

This withdrawal is based on the following reason:

CureVac AG made the strategic decision to focus its COVID-19 vaccine development on a second generation vaccine program.

Ongoing clinical trials with CVnCoV will be continued and finalized as planned including follow-up.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMA website.

Yours sincerely,

Executive Director Regulatory Affairs